Why the study?
Does transcatheter aortic valve replacement (TAVR) improve outcomes in low-risk patients with symptomatic severe aortic stenosis?
Meta-Analysis
Does transcatheter aortic valve replacement (TAVR) improve outcomes in low-risk patients with symptomatic severe aortic stenosis?
Answers are grounded in this paper and cite their sources.
Lifelong management decisions for TAVR in low-risk patients remain challenging despite promising long-term outcomes.
The use of transcatheter aortic valve replacement (TAVR) has progressively expanded as a treatment for symptomatic severe aortic stenosis. Current international guidelines provide a class I recommendation for patients with high-flow, high-gradient aortic stenosis regardless of surgical risk (1). However, lifelong management decisions in low-risk patients remain challenging. Although a previous meta-analysis suggested a lower risk of death with TAVR at 5-year follow-up, the inclusion of trials with shorter follow-up may have overestimated the early advantages of TAVR (2,3).
No takes yet. Share an insight, caveat, or question.
Pietro et al. (2026) conducted a meta-analysis in Symptomatic severe aortic stenosis in low-risk patients. Transcatheter aortic valve replacement (TAVR) was evaluated.
Synapse has enriched 10 related papers. Consider them for comparative context: